The incidence and implications of aldosterone breakthrough.
about
New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant HypertensionDual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney diseaseMineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!Mineralocorticoid receptor blockade in chronic kidney diseaseTherapeutic modalities in diabetic nephropathy: standard and emerging approaches.Mineralocorticoid receptor antagonists and endothelial functionManagement of Diabetic Nephropathy in the Elderly: Special Considerations.Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data.Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study.Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb.eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists.Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?Expression of ACE and ACE2 in patients with hypertensive nephrosclerosis.Efficacy of nebivolol-valsartan single-pill combination in obese and nonobese patients with hypertensionInterfering with mineralocorticoid receptor activation: the past, present, and futureAliskiren and valsartan combination therapy for the management of hypertension.Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease.Suppression of adrenal βarrestin1-dependent aldosterone production by ARBs: head-to-head comparison.Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosisHypertension in Cardiovascular and Kidney Disease.Midkine Regulates BP through Cytochrome P450-Derived Eicosanoids.Hypertension Management in Diabetic Kidney DiseaseThe safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.A Single-Center, Open-Label, 3-Way Crossover Trial to Determine the Pharmacokinetic and Pharmacodynamic Interaction Between Nebivolol and Valsartan in Healthy Volunteers at Steady State.Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients.Renal denervation for the treatment of resistant hypertension: review and clinical perspectiveARB protects podocytes from HIV-1 nephropathy independently of podocyte AT1.Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences.Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.Structure-activity relationship study of angiotensin II analogs in terms of β-arrestin-dependent signaling to aldosterone production.Angiotensin II AT1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal glandOptimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination.Prospective change in renal volume and function in children with ADPKD.Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis.Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertensionDeterminants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathyAldosterone and progression of kidney disease.Inhibition of the renin-angiotensin system and target organ protection.Mineralocorticoid receptor activation in obesity hypertension.
P2860
Q26748793-96192994-6AE8-4FA5-A160-C61669BA93ABQ26752292-E85C771B-475B-4B7F-8A4E-2DBF322276F9Q26776149-1677E8D8-2271-4180-9133-7666514E615FQ26864370-8A6C6A26-38AA-4A30-A773-C8C6F68116A8Q27007027-9F25BBA8-298B-4F39-8101-AD048EC6003FQ28645984-4604D5A4-E7EF-400E-83F4-18F6DD78211FQ30353386-369D5B33-3758-441F-89DD-BD0192C0E198Q30491698-81680D79-691C-4277-B2FC-6C26247896B7Q31118126-FFFA8B73-11E6-499A-BD6A-A3E15DA47F5FQ33568512-F8EF4DBB-8F65-4F7F-AA3C-DE4F4CFBAC28Q33597090-655D9065-CF4C-4883-AB09-3F5E82D11C5EQ33754669-B1C47E30-E6B6-4AE9-A574-EC50E1F5D3D8Q33827868-99E3C29C-FF46-4E54-895E-2CDDEA72AF66Q33834397-37C7D6DE-2FB4-49E3-B068-3A57E22D2EB9Q34019947-F6C35C8F-815F-4883-AA6D-0310FF6445F4Q34139070-754AA786-4A23-4659-8333-39B6644D6D31Q34604473-A2292EA6-B456-4F0C-B5AB-27B909775A40Q34714245-B52700FF-2505-4DB9-9A80-4752726798B3Q35024828-CE8B9016-A012-4922-8C6C-4EBB7A76D8E7Q35055052-4853FC2C-46A5-4F33-9B5D-42AF88DD373AQ35203404-DB4CC563-A7B3-4236-9151-A5CA7A8EDBD2Q35903066-C44A5EC4-88F1-4A76-837F-69B92E3ECAD5Q35953909-EE7C5A4B-0C6C-4645-9CB8-D3AB68EA9ED2Q36017400-70A4B247-93E1-40A5-9FAC-C5F5928D5DA4Q36098688-2D248CAD-B79C-4063-A470-86E9970127A3Q36106582-14EF3394-A31C-49DE-92A1-B502E4B0A841Q36122797-5249C9C2-050E-44E9-9EA2-D7F3FB2ECBF7Q36129864-8A59B427-FE8E-4C00-B3C5-BA83C2D632D2Q36329456-29D70E79-CC4E-4782-80B4-04A33FAB4C92Q36701736-80B3FD0E-FB5A-4BA4-ACDF-ADAF69EF95CEQ36719641-DD3FB64B-3E58-4C0D-AF03-DFE9983EEDABQ36972703-B76DE85E-73AC-47BC-B204-C4A4DE0A3F7DQ36975796-1C237054-AA19-4907-A919-3A39CEFE18CAQ37152490-B91CF2CC-A27B-49CA-8F62-B8BC20FB2965Q37168726-E8C8C5BF-8780-4F1C-89B6-4EF87394A492Q37186757-F3364AE5-3640-420D-94C0-F43DD79758BEQ37212380-78E13E70-5E44-4AB6-BF3A-0FBDE9881B12Q37378291-65CD6A57-419C-42E6-9FD7-98FA43540184Q37406883-2A2FD88B-57A6-40BE-91D9-03140DCAFDD5Q37517178-BFA4F212-CCA6-40BC-9D72-5187FB3A415A
P2860
The incidence and implications of aldosterone breakthrough.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The incidence and implications of aldosterone breakthrough.
@en
type
label
The incidence and implications of aldosterone breakthrough.
@en
prefLabel
The incidence and implications of aldosterone breakthrough.
@en
P356
P1476
The incidence and implications of aldosterone breakthrough.
@en
P2093
Andrew S Bomback
Philip J Klemmer
P2860
P304
P356
10.1038/NCPNEPH0575
P577
2007-09-01T00:00:00Z